181 related articles for article (PubMed ID: 15677882)
1. Implication of pituitary vasoactive intestinal peptide in dopaminergic inhibition of estrogen-induced pituitary hyperplasia and vascular endothelial growth factor expression.
Gómez O; Balsa JA
Neuroendocrinology; 2004; 80(5):324-31. PubMed ID: 15677882
[TBL] [Abstract][Full Text] [Related]
2. Autocrine/paracrine action of pituitary vasoactive intestinal peptide on lactotroph hyperplasia induced by estrogen.
Gómez O; Balsa JA
Endocrinology; 2003 Oct; 144(10):4403-9. PubMed ID: 12960047
[TBL] [Abstract][Full Text] [Related]
3. Autoparacrine action of vasoactive intestinal peptide on dopaminergic control of prolactin secretion.
Balsa JA; Sánchez-Franco F; Lorenzo MJ; Pazos F; Lara JI; Cacicedo L
Endocrinology; 1996 Feb; 137(2):508-13. PubMed ID: 8593796
[TBL] [Abstract][Full Text] [Related]
4. Prolactin gene expression and secretion during pregnancy and lactation in the rat: role of dopamine and vasoactive intestinal peptide.
Escalada J; Cacicedo L; Ortego J; Melian E; Sánchez-Franco F
Endocrinology; 1996 Feb; 137(2):631-7. PubMed ID: 8593812
[TBL] [Abstract][Full Text] [Related]
5. Preferential increase in pituitary prolactin versus vasoactive intestinal peptide as a function of estradiol benzoate dose in the ovariectomized rat.
Carrillo AJ; Doherty PC; Guan XB; Sturtevant JR; Walro DG
Endocrinology; 1991 Jan; 128(1):131-8. PubMed ID: 1986914
[TBL] [Abstract][Full Text] [Related]
6. Inhibitory effect of thalidomide on the growth, secretory function and angiogenesis of estrogen-induced prolactinoma in Fischer 344 rats.
Stepień H; Lawnicka H; Mucha S; Wagrowska-Danilewicz M; Stepień B; Siejka A; Komorowski J
Life Sci; 2006 Sep; 79(18):1741-8. PubMed ID: 16846617
[TBL] [Abstract][Full Text] [Related]
7. Vasoactive intestinal peptide stimulates prolactin mRNA expression in turkey pituitary cells: effects of dopaminergic drugs.
Xu M; Proudman JA; Pitts GR; Wong EA; Foster DN; el Halawani ME
Proc Soc Exp Biol Med; 1996 May; 212(1):52-62. PubMed ID: 8618952
[TBL] [Abstract][Full Text] [Related]
8. Inhibitory effects of antivascular endothelial growth factor strategies in experimental dopamine-resistant prolactinomas.
Luque GM; Perez-Millán MI; Ornstein AM; Cristina C; Becu-Villalobos D
J Pharmacol Exp Ther; 2011 Jun; 337(3):766-74. PubMed ID: 21406548
[TBL] [Abstract][Full Text] [Related]
9. Effects of nitric oxide synthase inhibition on diethylstilbestrol-induced hyperprolactinaemia and pituitary tumourigenesis in rats.
Pawlikowski M; Pisarek H; Fryczak J; Stępień H
Endokrynol Pol; 2012; 63(2):115-8. PubMed ID: 22538750
[TBL] [Abstract][Full Text] [Related]
10. Chronic estrogen treatment promotes a functional uncoupling of the D2 dopamine receptor in rat anterior pituitary gland.
Munemura M; Agui T; Sibley DR
Endocrinology; 1989 Jan; 124(1):346-55. PubMed ID: 2521206
[TBL] [Abstract][Full Text] [Related]
11. Effects of estrogen and tamoxifen on the ultrastructural characteristics of female rat prolactin cells as evaluated by immunogold technique.
Erensoy N; Cagatay P; Yilmazer S
Acta Histochem; 2005; 107(3):199-205. PubMed ID: 15993477
[TBL] [Abstract][Full Text] [Related]
12. Hyperprolactinemia reduces vasoactive intestinal peptide in the anterior pituitary glands of rats.
Prysor-Jones RA; Silverlight JJ; Jenkins JS
Neurosci Lett; 1987 Oct; 80(3):333-8. PubMed ID: 3683988
[TBL] [Abstract][Full Text] [Related]
13. PTTG expression in different experimental and human prolactinomas in relation to dopaminergic control of lactotropes.
Cristina C; Díaz-Torga GS; Goya RG; Kakar SS; Perez-Millán MI; Passos VQ; Giannella-Neto D; Bronstein MD; Becu-Villalobos D
Mol Cancer; 2007 Jan; 6():4. PubMed ID: 17222350
[TBL] [Abstract][Full Text] [Related]
14. Involvement of vasoactive intestinal peptide on insulin-like growth factor I-induced proliferation of rat pituitary lactotropes in primary culture: evidence for an autocrine and/or paracrine regulatory system.
Fernández M; Sánchez-Franco F; Palacios N; Sánchez I; Villuendas G; Cacicedo L
Neuroendocrinology; 2003 May; 77(5):341-52. PubMed ID: 12806180
[TBL] [Abstract][Full Text] [Related]
15. Increased pituitary vascular endothelial growth factor-a in dopaminergic D2 receptor knockout female mice.
Cristina C; Díaz-Torga G; Baldi A; Góngora A; Rubinstein M; Low MJ; Becú-Villalobos D
Endocrinology; 2005 Jul; 146(7):2952-62. PubMed ID: 15817666
[TBL] [Abstract][Full Text] [Related]
16. Bromocriptine inhibits galanin gene expression in the rat pituitary gland.
Leite V; Vrontakis ME; Kasper S; Friesen HG
Mol Cell Neurosci; 1993 Oct; 4(5):418-23. PubMed ID: 19912948
[TBL] [Abstract][Full Text] [Related]
17. Vasoactive intestinal peptide in rats with focal cerebral ischemia enhances angiogenesis.
Yang J; Zong CH; Zhao ZH; Hu XD; Shi QD; Xiao XL; Liu Y
Neuroscience; 2009 Jun; 161(2):413-21. PubMed ID: 19332106
[TBL] [Abstract][Full Text] [Related]
18. Regulation of prolactin gene expression by vasoactive intestinal peptide and dopamine in the turkey: role of Ca signalling.
Al Kahtane A; Kannan M; Kang SW; El Halawani ME
J Neuroendocrinol; 2005 Oct; 17(10):649-55. PubMed ID: 16159377
[TBL] [Abstract][Full Text] [Related]
19. Vasoactive intestinal polypeptide antiserum affects rat prolactin mRNA in 40-day but not 110-day diethylstilbestrol-induced prolactinoma tissue.
Maas DL; Meier DA; Wahle JS; Martinson DR; Hagen TC
Mol Cell Neurosci; 1994 Apr; 5(2):182-8. PubMed ID: 8032686
[TBL] [Abstract][Full Text] [Related]
20. Serotonergic involvement in the regulation of prolactin and vasoactive intestinal peptide mRNA expression in the rat anterior pituitary.
Signs SA; Liu B; Wolford J; Carrillo AJ
Mol Cell Endocrinol; 1994 Nov; 105(2):183-91. PubMed ID: 7859924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
